Selected research
Industry Research
Insulin Like Growth Factor 1 Receptor Industry Research Report 2026
Market perspective
The global Insulin Like Growth Factor 1 Receptor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Insulin Like Growth Factor 1 Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Insulin Like Growth Factor 1 Receptor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Insulin Like Growth Factor 1 Receptor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Insulin Like Growth Factor 1 Receptor include Novartis AG, Merck & Co., Inc., Eli Lilly and Company, AstraZeneca Plc, ProteoThera, Inc., PharmAbcine, Inc., Merrimack Pharmaceuticals, Inc., Insmed Incorporated and Immunomedics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Insulin Like Growth Factor 1 Receptor market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Insulin Like Growth Factor 1 Receptor Market by Company
Novartis AG
Merck & Co., Inc.
Eli Lilly and Company
AstraZeneca Plc
ProteoThera, Inc.
PharmAbcine, Inc.
Merrimack Pharmaceuticals, Inc.
Insmed Incorporated
Immunomedics, Inc.
Genmab A/S
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Axelar AB
Astellas Pharma Inc.
Insulin Like Growth Factor 1 Receptor Segment by Type
CT-707
BI-893923
ATL-1101
1R-E1
Others
Insulin Like Growth Factor 1 Receptor Segment by Application
Hospital
Clinic
Others
Insulin Like Growth Factor 1 Receptor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Like Growth Factor 1 Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Like Growth Factor 1 Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Like Growth Factor 1 Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Insulin Like Growth Factor 1 Receptor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Insulin Like Growth Factor 1 Receptor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Insulin Like Growth Factor 1 Receptor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CT-707
- BI-893923
- ATL-1101
- 1R-E1
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly and Company
- AstraZeneca Plc
- ProteoThera, Inc.
- PharmAbcine, Inc.
- Merrimack Pharmaceuticals, Inc.
- Insmed Incorporated
- Immunomedics, Inc.
- Genmab A/S
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Axelar AB
- Astellas Pharma Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Insulin Like Growth Factor 1 Receptor Market Size (2021-2032)
- 2.2.2 Global Insulin Like Growth Factor 1 Receptor Sales (2021-2032)
- 2.2.3 Global Insulin Like Growth Factor 1 Receptor Market Average Price (2021-2032)
- 2.3 Insulin Like Growth Factor 1 Receptor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CT-707
- 2.3.3 BI-893923
- 2.3.4 ATL-1101
- 2.3.5 1R-E1
- 2.3.6 Others
- 2.4 Insulin Like Growth Factor 1 Receptor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Insulin Like Growth Factor 1 Receptor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Insulin Like Growth Factor 1 Receptor Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Insulin Like Growth Factor 1 Receptor Revenue of Manufacturers (2021-2026)
- 3.4 Global Insulin Like Growth Factor 1 Receptor Average Price by Manufacturers (2021-2026)
- 3.5 Global Insulin Like Growth Factor 1 Receptor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Insulin Like Growth Factor 1 Receptor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Insulin Like Growth Factor 1 Receptor, Product Type & Application
- 3.8 Global Manufacturers of Insulin Like Growth Factor 1 Receptor, Established Date
- 3.9 Global Insulin Like Growth Factor 1 Receptor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Eli Lilly and Company
- 4.3.1 Eli Lilly and Company Company Information
- 4.3.2 Eli Lilly and Company Business Overview
- 4.3.3 Eli Lilly and Company Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly and Company Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.3.5 Eli Lilly and Company Recent Developments
- 4.4 AstraZeneca Plc
- 4.4.1 AstraZeneca Plc Company Information
- 4.4.2 AstraZeneca Plc Business Overview
- 4.4.3 AstraZeneca Plc Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Plc Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.4.5 AstraZeneca Plc Recent Developments
- 4.5 ProteoThera, Inc.
- 4.5.1 ProteoThera, Inc. Company Information
- 4.5.2 ProteoThera, Inc. Business Overview
- 4.5.3 ProteoThera, Inc. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 ProteoThera, Inc. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.5.5 ProteoThera, Inc. Recent Developments
- 4.6 PharmAbcine, Inc.
- 4.6.1 PharmAbcine, Inc. Company Information
- 4.6.2 PharmAbcine, Inc. Business Overview
- 4.6.3 PharmAbcine, Inc. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 PharmAbcine, Inc. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.6.5 PharmAbcine, Inc. Recent Developments
- 4.7 Merrimack Pharmaceuticals, Inc.
- 4.7.1 Merrimack Pharmaceuticals, Inc. Company Information
- 4.7.2 Merrimack Pharmaceuticals, Inc. Business Overview
- 4.7.3 Merrimack Pharmaceuticals, Inc. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merrimack Pharmaceuticals, Inc. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.7.5 Merrimack Pharmaceuticals, Inc. Recent Developments
- 4.8 Insmed Incorporated
- 4.8.1 Insmed Incorporated Company Information
- 4.8.2 Insmed Incorporated Business Overview
- 4.8.3 Insmed Incorporated Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Insmed Incorporated Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.8.5 Insmed Incorporated Recent Developments
- 4.9 Immunomedics, Inc.
- 4.9.1 Immunomedics, Inc. Company Information
- 4.9.2 Immunomedics, Inc. Business Overview
- 4.9.3 Immunomedics, Inc. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Immunomedics, Inc. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.9.5 Immunomedics, Inc. Recent Developments
- 4.10 Genmab A/S
- 4.10.1 Genmab A/S Company Information
- 4.10.2 Genmab A/S Business Overview
- 4.10.3 Genmab A/S Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Genmab A/S Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.10.5 Genmab A/S Recent Developments
- 4.11 F. Hoffmann-La Roche Ltd.
- 4.11.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.11.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.11.3 F. Hoffmann-La Roche Ltd. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 F. Hoffmann-La Roche Ltd. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.11.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.12 Bristol-Myers Squibb Company
- 4.12.1 Bristol-Myers Squibb Company Company Information
- 4.12.2 Bristol-Myers Squibb Company Business Overview
- 4.12.3 Bristol-Myers Squibb Company Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol-Myers Squibb Company Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.12.5 Bristol-Myers Squibb Company Recent Developments
- 4.13 Boehringer Ingelheim GmbH
- 4.13.1 Boehringer Ingelheim GmbH Company Information
- 4.13.2 Boehringer Ingelheim GmbH Business Overview
- 4.13.3 Boehringer Ingelheim GmbH Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Boehringer Ingelheim GmbH Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.13.5 Boehringer Ingelheim GmbH Recent Developments
- 4.14 Axelar AB
- 4.14.1 Axelar AB Company Information
- 4.14.2 Axelar AB Business Overview
- 4.14.3 Axelar AB Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Axelar AB Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.14.5 Axelar AB Recent Developments
- 4.15 Astellas Pharma Inc.
- 4.15.1 Astellas Pharma Inc. Company Information
- 4.15.2 Astellas Pharma Inc. Business Overview
- 4.15.3 Astellas Pharma Inc. Insulin Like Growth Factor 1 Receptor Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Astellas Pharma Inc. Insulin Like Growth Factor 1 Receptor Product Portfolio
- 4.15.5 Astellas Pharma Inc. Recent Developments
5 Global Insulin Like Growth Factor 1 Receptor Market Scenario by Region
- 5.1 Global Insulin Like Growth Factor 1 Receptor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Insulin Like Growth Factor 1 Receptor Sales by Region: 2021-2032
- 5.2.1 Global Insulin Like Growth Factor 1 Receptor Sales by Region: 2021-2026
- 5.2.2 Global Insulin Like Growth Factor 1 Receptor Sales by Region: 2027-2032
- 5.3 Global Insulin Like Growth Factor 1 Receptor Revenue by Region: 2021-2032
- 5.3.1 Global Insulin Like Growth Factor 1 Receptor Revenue by Region: 2021-2026
- 5.3.2 Global Insulin Like Growth Factor 1 Receptor Revenue by Region: 2027-2032
- 5.4 North America Insulin Like Growth Factor 1 Receptor Market Facts & Figures by Country
- 5.4.1 North America Insulin Like Growth Factor 1 Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Insulin Like Growth Factor 1 Receptor Sales by Country (2021-2032)
- 5.4.3 North America Insulin Like Growth Factor 1 Receptor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Insulin Like Growth Factor 1 Receptor Market Facts & Figures by Country
- 5.5.1 Europe Insulin Like Growth Factor 1 Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Insulin Like Growth Factor 1 Receptor Sales by Country (2021-2032)
- 5.5.3 Europe Insulin Like Growth Factor 1 Receptor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Insulin Like Growth Factor 1 Receptor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Insulin Like Growth Factor 1 Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Insulin Like Growth Factor 1 Receptor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Insulin Like Growth Factor 1 Receptor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Insulin Like Growth Factor 1 Receptor Market Facts & Figures by Country
- 5.7.1 South America Insulin Like Growth Factor 1 Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Insulin Like Growth Factor 1 Receptor Sales by Country (2021-2032)
- 5.7.3 South America Insulin Like Growth Factor 1 Receptor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Insulin Like Growth Factor 1 Receptor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Insulin Like Growth Factor 1 Receptor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Insulin Like Growth Factor 1 Receptor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Insulin Like Growth Factor 1 Receptor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Insulin Like Growth Factor 1 Receptor Sales by Type (2021-2032)
- 6.1.1 Global Insulin Like Growth Factor 1 Receptor Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Insulin Like Growth Factor 1 Receptor Sales Market Share by Type (2021-2032)
- 6.2 Global Insulin Like Growth Factor 1 Receptor Revenue by Type (2021-2032)
- 6.2.1 Global Insulin Like Growth Factor 1 Receptor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Insulin Like Growth Factor 1 Receptor Revenue Market Share by Type (2021-2032)
- 6.3 Global Insulin Like Growth Factor 1 Receptor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Insulin Like Growth Factor 1 Receptor Sales by Application (2021-2032)
- 7.1.1 Global Insulin Like Growth Factor 1 Receptor Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Insulin Like Growth Factor 1 Receptor Sales Market Share by Application (2021-2032)
- 7.2 Global Insulin Like Growth Factor 1 Receptor Revenue by Application (2021-2032)
- 7.2.1 Global Insulin Like Growth Factor 1 Receptor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Insulin Like Growth Factor 1 Receptor Revenue Market Share by Application (2021-2032)
- 7.3 Global Insulin Like Growth Factor 1 Receptor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Insulin Like Growth Factor 1 Receptor Value Chain Analysis
- 8.1.1 Insulin Like Growth Factor 1 Receptor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Insulin Like Growth Factor 1 Receptor Production Mode & Process
- 8.2 Insulin Like Growth Factor 1 Receptor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Insulin Like Growth Factor 1 Receptor Distributors
- 8.2.3 Insulin Like Growth Factor 1 Receptor Customers
9 Global Insulin Like Growth Factor 1 Receptor Analyzing Market Dynamics
- 9.1 Insulin Like Growth Factor 1 Receptor Industry Trends
- 9.2 Insulin Like Growth Factor 1 Receptor Industry Drivers
- 9.3 Insulin Like Growth Factor 1 Receptor Industry Opportunities and Challenges
- 9.4 Insulin Like Growth Factor 1 Receptor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst